• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物诱导的 CTLA-4 受体抑制相关格雷夫斯病。

Drug-induced graves disease from CTLA-4 receptor suppression.

机构信息

Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02142, USA.

出版信息

Ophthalmic Plast Reconstr Surg. 2011 Jul-Aug;27(4):e87-8. doi: 10.1097/IOP.0b013e3181ef72a1.

DOI:10.1097/IOP.0b013e3181ef72a1
PMID:21242854
Abstract

Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.

摘要

单克隆抗体,易普利姆玛,可用于治疗转移性黑色素瘤,可阻断 CTLA-4 介导的 T 细胞抑制,也可引起格雷夫斯眼病样综合征。流行病学研究将 CTLA-4 受体基因的变异多态性与甲状腺眼病的存在联系起来。这些观察结果的结合表明 CTLA-4 介导的 T 细胞功能对甲状腺相关眼病的发病机制很重要。

相似文献

1
Drug-induced graves disease from CTLA-4 receptor suppression.药物诱导的 CTLA-4 受体抑制相关格雷夫斯病。
Ophthalmic Plast Reconstr Surg. 2011 Jul-Aug;27(4):e87-8. doi: 10.1097/IOP.0b013e3181ef72a1.
2
Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".关于:“CTLA-4受体抑制引发的药物性格雷夫斯病”
Ophthalmic Plast Reconstr Surg. 2013 May-Jun;29(3):239-40. doi: 10.1097/IOP.0b013e3182895795.
3
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression".回复:关于“CTLA - 4受体抑制导致药物性格雷夫斯病”
Ophthalmic Plast Reconstr Surg. 2013 May-Jun;29(3):241. doi: 10.1097/IOP.0b013e31828957c3.
4
Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab.接受伊匹单抗治疗的甲状腺功能正常患者出现类似甲状腺的眼病。
Orbit. 2014 Dec;33(6):424-7. doi: 10.3109/01676830.2014.949792. Epub 2014 Sep 10.
5
Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.伊匹单抗诱导的眼眶炎症,类似格雷夫斯病,随后因细胞毒性T淋巴细胞相关抗原4(CTLA-4)受体抑制而出现全身性甲状腺功能亢进。
Ophthalmic Plast Reconstr Surg. 2014 Jan-Feb;30(1):83. doi: 10.1097/IOP.0000000000000033.
6
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.CTLA-4 抗体治疗转移性黑色素瘤的治疗和副作用管理。
J Dtsch Dermatol Ges. 2011 Apr;9(4):277-86. doi: 10.1111/j.1610-0387.2010.07568.x. Epub 2010 Nov 17.
7
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.抗 CTLA-4 抗体免疫治疗黑色素瘤的最新进展:识别临床和生物学反应模式、免疫相关不良反应及其管理。
Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003.
8
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.综述:抗CTLA-4抗体伊匹单抗:临床反应及免疫相关不良事件的病例研究
Oncologist. 2007 Jul;12(7):864-72. doi: 10.1634/theoncologist.12-7-864.
9
[Orbital myositis associated with ipilimumab].[与伊匹单抗相关的眼眶肌炎]
Ann Dermatol Venereol. 2013 Jun-Jul;140(6-7):448-51. doi: 10.1016/j.annder.2013.02.029. Epub 2013 May 9.
10
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.甲状腺自身免疫和眼病与黑色素瘤生物治疗相关。
Eur J Endocrinol. 2011 Feb;164(2):303-7. doi: 10.1530/EJE-10-0833. Epub 2010 Nov 18.

引用本文的文献

1
Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation.病例报告:免疫检查点抑制剂起始治疗后严重炎性眼眶病的发生
Front Ophthalmol (Lausanne). 2025 Jun 3;5:1574643. doi: 10.3389/fopht.2025.1574643. eCollection 2025.
2
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes.免疫检查点抑制剂相关甲状腺炎:机制与临床结局
J Endocrinol Invest. 2025 Sep;48(9):2001-2012. doi: 10.1007/s40618-025-02608-2. Epub 2025 May 12.
3
Real-World Evaluation of Immune-Related Endocrinopathies in Metastatic NSCLC Patients Treated with ICIs in Romania.
罗马尼亚接受免疫检查点抑制剂治疗的转移性非小细胞肺癌患者免疫相关内分泌病的真实世界评估
Cancers (Basel). 2025 Mar 31;17(7):1198. doi: 10.3390/cancers17071198.
4
Immune Checkpoints and Graves' Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review.免疫检查点与格雷夫斯病、甲状腺眼病和眼眶肌病:综述
J Ophthalmic Vis Res. 2024 Sep 16;19(3):368-380. doi: 10.18502/jovr.v19i3.15047. eCollection 2024 Jul-Sep.
5
Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.免疫检查点:甲状腺眼病发病机制的新见解。
Front Immunol. 2024 May 16;15:1392956. doi: 10.3389/fimmu.2024.1392956. eCollection 2024.
6
Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.眼眶中的免疫过程以及当前和潜在药物靶点的适应症
J Clin Med. 2023 Dec 22;13(1):72. doi: 10.3390/jcm13010072.
7
Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer.癌症免疫检查点抑制剂治疗后免疫相关内分泌病的诊断标准及建议管理
Endocr Connect. 2023 Apr 17;12(5). doi: 10.1530/EC-22-0513. Print 2023 May 1.
8
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.与免疫检查点抑制剂相关的眼部不良事件:一项范围综述
J Ophthalmic Inflamm Infect. 2023 Feb 22;13(1):5. doi: 10.1186/s12348-022-00321-2.
9
Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.免疫检查点抑制剂相关内分泌功能障碍患者的处理方法。
J Clin Endocrinol Metab. 2023 May 17;108(6):1514-1525. doi: 10.1210/clinem/dgac689.
10
Ocular Inflammation Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂引起的眼部炎症。
J Clin Med. 2022 Aug 25;11(17):4993. doi: 10.3390/jcm11174993.